In stage I and II cancer patients, anti-AEG-1 antibody was detected in 31% cases that include 30% breast cancer, 26% HCC, 35% colorectal cancer, 30% lung cancer and 39% gastric cancer patients [133]. Here, MTDH is linked to breast carcinoma.